[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Терапевтический архив

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 23819335
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

  2012cited by this paper
• Biologic Therapy for Rheumatoid Arthritis

  2012cited by this paper
• Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

  2011cited by this paper
• Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data

  2011cited by this paper
• Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study

  2011cited by this paper
• Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlle

  2010cited by this paper
• Tocilizumab: a review of its use in the management of rheumatoid arthritis.

  2009cited by this paper
• The problem of rheumatoid arthritis disease activity and remission in clinical practice.

  2008cited by this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008cited by this paper
• Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis.

  2007cited by this paper
• Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.

  2007cited by this paper
• Cytokines in the pathogenesis of rheumatoid arthritis

  2007cited by this paper
• Matrix metalloproteinases: role in arthritis.

  2006cited by this paper
• A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

  2003cited by this paper
• Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

  2003cited by this paper
• Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.

  2003cited by this paper
• Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

  2002cited by this paper
• Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment

  2002cited by this paper
• Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

  2002cited by this paper
• Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.

  2002cited by this paper
• Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not.

  2000cited by this paper
• Changes in cartilage composition and physical properties due to stromelysin degradation.

  1995cited by this paper
• Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two metalloproteinases by interferon-gamma.

  1991cited by this paper

• Interleukin-6 blockers improve inflammation-induced lipid metabolism impairments but induce liver fibrosis in collagen-induced arthritis.

  2022cites this paper
• MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis.

  2018cites this paper
• Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy.

  2015cites this paper
• Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.

  2014cites this paper
• Клиническое значение матриксных металлопротеиназ при ревматоидном артрите (обзор литературы и собственные данные)

  2014cites this paper